Insomnia Market
Report ID: SQMIG35I3042
Report ID: SQMIG35I3042
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3042 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
174
|Figures:
79
Global Insomnia Market size was valued at USD 4.87 Billion in 2024 and is poised to grow from USD 5.17 Billion in 2025 to USD 8.37 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).
The insomnia market encompasses products that diagnose, treat and/or manage the challenges of falling asleep and/or staying asleep (drugs, supplements, wearables, etc.). Multiple reasons exist for the importance of the insomnia market, including the fact that insomnia leads to chronic illness, decreased productivity and increased national health care expenditures on a global level. The primary driving force behind the growth of the insomnia market is the rapidly increasing prevalence of sleep disturbance, which significant research has shown to be related to the ever-increasing amount of time individuals spend consuming media (e.g., television, computers, and smartphones), the increasing prevalence of stress from work and home, and the increasing number of individuals living longer with different circadian rhythms due to age. Initially, benzodiazepines were the primary therapies prescribed to treat insomnia; however, the emergence of safety concerns has shifted the focus to orexin antagonists, melatonin and behavioral therapies through mobile applications.
The recent approval by the FDA of lemborexant and the rapidly growing population of sleep tracker users illustrate how the insomnia market is evolving from being a traditional pharmaceutical-based treatment model to one that is primarily technology based. Digital therapeutics will also help drive market growth through the pairing of patient data analytics with personalized, evidence-based behavioral therapies containing no medications, thus providing value-added interventions outside of medication. As patients increasingly prefer medication-free solutions to treat insomnia, insurers are now reimbursing for CBT-I mobile application usage, reducing average per patient costs and further encouraging investment in the mobile application platforms used to deliver treatment.
Pear Therapeutics and Sunovion have both recently brought to market corporation-based programs that use mobile sleep diaries and machine learning algorithms to assist users in going to bed and staying asleep for longer periods of time. Corporate wellness schemes now embed these tools into employee health benefits, creating B2B revenue streams and reinforcing market expansion.
How are AI and IoT Innovations Reshaping The Insomnia Market?
The use of artificial intelligence (AI)-driven platforms is revolutionizing the way clinicians use raw sleep data to develop treatment plans and enable real-time patient monitoring of their sleep progress. Machine learning algorithms can review historical and current usage from wearable devices, smart beds, and mobile apps, to identify significant patterns and determine triggers such as irregular schedules and stress. This information can then be used to provide non-pharmacologic (or alternative) options to patients before prescribing typical medications to treat insomnia.
IoT (internet of things) enabled devices (e.g., connected CPAP machines, ambient sensors) are able to automatically adjust (via changing temperature, pressure, light) to create the best possible conditions for sleep without any manual intervention. These developments in sleep technology have resulted in decreased reliance on trial-and-error prescribing, increased patient compliance, and increased availability of remote care, thus providing a more effective and patient-centered delivery of treatment in a rapidly growing market. In June 2024, ResMed introduced the New AI Sleep Tracking System, which uses its connected IoT CPAP devices to customize patient therapy based on real-time nightly data and enables quicker and more accurate management of insomnia.
Market snapshot - (2026-2033)
Global Market Size
USD 4.87 Billion
Largest Segment
Pharmacological Treatment
Fastest Growth
Medical Devices
Growth Rate
6.2% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global insomnia market is segmented by treatment type, insomnia type, drug class, end user, patient group, distribution channel and region. Based on treatment type, the market is segmented into Pharmacological Treatment, Cognitive Behavioral Therapy, Medical Devices and Others. Based on insomnia type, the market is segmented into Acute Insomnia, Chronic Insomnia and Comorbid Insomnia. Based on drug class, the market is segmented into Benzodiazepines, Dual Orexin Receptor Antagonists, Melatonin Receptor Agonists and Others. Based on end user, the market is segmented into Hospitals, Sleep Clinics, Homecare Settings and Others. Based on patient group, the market is segmented into Adult Patients and Geriatric Patients. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Pharmacological Treatment segment primarily holds the largest share of market revenue due to providing patients with the most rapid removal from their symptoms as well as having decades of evidence-based support. Due to predictable dosing, insurance reimbursement and the standard prescribing pathways for patients beginning drug therapy, many physicians prefer to prescribe medication as it facilitates patients adopting this type of therapy. Additionally, the variety of compounds available to treat insomnia include both traditional medication classes and newer drug classes meet patients’ needs with an extensive range of options to meet patient’s needs reinforces their position as the primary component within various therapeutic algorithms thereby continuing to dominate the total global insomnia therapeutic market.
The Medical Devices sub‑segment is quickly gaining traction and is already emerging as one of the largest high-growth segments within the Insomnia Market. Advances in consumer & clinical applications associated with wearable sleep tracking devices as well as non-invasive stimulation devices have greatly expanded both the consumer and provider driven segments. The tremendous demand from consumers for extensive data with at-home options has led to rapid growth rates of this sub‑segment. Continuous innovation will further expand the therapeutic indications, which will facilitate growth in the marketplace and create new liquidity sources for providers.
The dual orexin receptor antagonists segment has continued growth by providing a new mechanism that directly activates the pathway that promotes wakefulness. These medications allow sleep onset and do not result in the tiredness associated with previous agents. Clinicians have found that these medications have a positive safety profile, particularly in patients with other medical issues, which has helped facilitate their prescribing confidence. The medical advances associated with these agents have kept pace with evolving clinical practice guidelines, confirming their importance in treatment protocols and enhancing their standing as the primary agents in treating insomnia among all groups of patients globally.
Conversely, the melatonin-receptor agonists sub-segment continues to show strong growth rates due to consumers increasingly seeking natural-source sleep aids, coupled with large increases in the availability of these products through over-the-counter (OTC) channels. As there is now clearer guidance from regulators regarding the use of lower-dose formulations, there will be greater acceptance of melatonin products. In addition, new studies will add to the list of indications for melatonin, establishing this class of medications as a key contributor to, and driver of, future growth and diversification within the insomnia market.
To get detailed segments analysis, Request a Free Sample Report
The North American insomnia market is the largest in the world due to a number of factors: sophisticated health care systems; consumer awareness about the importance of sleep; investment in pharmaceutical research and development. The United States has a developed health care delivery system with access to major research universities, clinical centres for sleep disorders, and an regulatory system that encourages rapid product development. In addition, Canada’s large investment in public health initiatives allows Canadians to have access to specialists trained in sleep medicine, and health care providers within the public sector and private sector work together to ensure patients receive high-quality care. A patient’s ability to access prescription and behavioral therapy for sleep disorders is facilitated by reimbursement models that partially reimburse patients for both types of therapy, while individuals are increasingly using wearable devices that track sleep patterns to monitor their sleep and drive demand for integrated treatment options. There is a strong venture capital presence in the region and this supports quick access to new treatments, thus initiating a cycle of creation that expands available treatment options to people with insomnia.
The Insomnia Market in the U.S. has many different forms of clinical research networks as well as a high number of sleep-related providers who have a high volume of patient care. Consumers are willing to go the extra mile to find professional help along with companies aggressively marketing both prescription and over-the-counter solutions. The integration of digital health platforms allows for correct diagnosis millions of people every year; additionally, insurance coverage policies help in expanding access to both pharmacologic and behavioral therapies which remain dynamic markets. Finally, health providers actively promote personalized care plans to help patients gain long-term comfort and health.
Due to Canada's publicly funded healthcare system, the Insomnia Market in Canada supports the early detection and treatment of sleeping disorders. With national guidelines issuing standards for combining medication and cognitive-behavioural therapy approaches, providers collaborate to provide a clearer pathway for patients moving from the primary care to the sleep clinic physician. As well, with the implementation of telemedicine, the growth of telemedicine is allowing providers to support individuals living in rural locations; in addition to fostering an innovation of products developed by clinical research institutions, the Insomnia Market continues to remain a stable market while evolving in the future.
Europe experiences rapid expansion in the insomnia market driven by heightened public health focus on sleep quality, progressive regulatory frameworks, and a unified push toward integrated care models. Germany leads with extensive clinical trial infrastructure and strong pharmaceutical expertise, while the United Kingdom’s agile adoption of digital health solutions accelerates product uptake. France’s emerging emphasis on preventive sleep health and reimbursement reforms stimulates market entry for innovative therapies. Cross‑border collaboration within the European Union facilitates knowledge sharing and harmonized guidelines, enabling swift dissemination of best practices. Consumer awareness campaigns and the growing popularity of evidence‑based behavioral interventions further reinforce demand, creating a fertile environment for both traditional medicines and next‑generation digital therapeutics. Healthcare payers are increasingly incorporating sleep assessments into routine evaluations, encouraging early intervention and expanding the patient pool eligible for treatment.
Insomnia Market in Germany is anchored by a robust research ecosystem and strong collaboration between pharmaceutical firms and academic institutions. Stringent yet clear regulatory pathways enable swift approval of novel compounds, while reimbursement policies support both medication and cognitive‑behavioral programs. High physician awareness and patient willingness to engage in multidisciplinary treatment plans drive sustained market activity, and the country’s emphasis on precision medicine fosters tailored therapeutic options for diverse patient profiles.
Insomnia Market in the United Kingdom is propelled by rapid digital health adoption and a proactive regulatory environment that encourages innovative therapeutic platforms. Public health initiatives highlight the economic burden of untreated sleep disorders, prompting insurers to expand coverage for both pharmacological and digital interventions. Strong ties between clinical research centers and technology firms accelerate the development of app‑based cognitive‑behavioral solutions, while a culturally progressive attitude toward mental wellbeing enhances patient acceptance of comprehensive sleep care.
Insomnia Market in France is emerging through focused preventive strategies and evolving reimbursement structures that favor innovative sleep therapies. National health agencies prioritize sleep health education, increasing public demand for evidence‑based treatments. Collaborative networks linking universities, hospitals, and biotech startups nurture the pipeline of novel compounds and digital tools. As insurers broaden coverage to include behavioral interventions, clinicians are better equipped to prescribe integrated solutions, stimulating gradual but steady market growth.
Asia Pacific is strengthening its position in the insomnia market by leveraging rapid technological advancement, expanding healthcare access, and a cultural shift toward recognizing sleep as essential to overall wellbeing. Japan combines a legacy of rigorous clinical research with a growing appetite for digital therapeutics, while South Korea excels in integrating wearable technology with real‑time monitoring platforms. Government initiatives across the region promote telehealth adoption and streamline approval pathways for innovative treatments. Rising middle‑class populations increase demand for both prescription options and lifestyle‑based interventions. Collaborative ventures between multinational pharmaceutical firms and local tech startups accelerate product localization, and heightened consumer education campaigns demystify sleep disorders, fostering a more proactive treatment landscape. Healthcare providers are increasingly incorporating sleep assessments into routine check‑ups, and insurers are broadening coverage to include emerging therapy modalities, further cementing the region’s market momentum.
Insomnia Market in Japan is characterized by a strong tradition of evidence‑driven clinical practice and an enthusiastic embrace of digital health solutions. Government support for telemedicine and expedited regulatory review of novel sleep medications encourage rapid market entry. High smartphone penetration facilitates widespread adoption of app‑based cognitive‑behavioral programs, while collaboration between pharmaceutical companies and technology firms spurs innovative combination therapies. Patient awareness campaigns further drive acceptance of both pharmacologic and non‑pharmacologic interventions.
Insomnia Market in South Korea thrives on a synergistic blend of cutting‑edge wearable technology and a proactive healthcare system. Rapid integration of real‑time sleep tracking into clinical protocols enables personalized treatment plans, while government incentives promote the development of novel pharmaceutical agents. Collaboration between major hospitals and fintech startups accelerates the rollout of subscription‑based digital therapy platforms. Growing consumer openness to mental health services reinforces demand for comprehensive sleep solutions across both urban and suburban populations.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Awareness of Sleep Health
Increasing Access to Digital Therapies
Limited Reimbursement for Treatments
Stigma Associated with Sleep Disorders
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global insomnia market is shaped by intense rivalry among digital‑therapeutics firms, pharmaceutical companies, and consumer‑tech players, each leveraging technology, strategic acquisitions, and partnerships to capture users seeking non‑pharmacologic solutions; recent M&A activity such as a major sleep‑device maker acquiring a CBT‑I app provider, and collaborations like a leading AI startup embedding generative models into personalized insomnia treatment platforms, are accelerating product differentiation and market penetration.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global insomnia market is projected to reach $8.37 billion by 2033, driven primarily by growing awareness of sleep health that pushes more patients to seek professional treatment, while the rapid expansion of digital therapies offers convenient, cost‑effective options and fuels a second growth engine. The pharmacological treatment segment remains dominant, reflecting clinicians’ preference for proven drug therapies. North America leads the market due to its advanced healthcare infrastructure and strong investment in both drugs and digital solutions. However, limited reimbursement for many therapies restrains broader adoption, creating a hurdle that could temper demand overall. Addressing these challenges will be crucial for sustaining momentum.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 4.87 Billion |
| Market size value in 2033 | USD 8.37 Billion |
| Growth Rate | 6.2% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Insomnia Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Insomnia Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Insomnia Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Insomnia Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Insomnia Market size was valued at USD 4.87 Billion in 2024 and is poised to grow from USD 5.17 Billion in 2025 to USD 8.37 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).
The competitive landscape of the global insomnia market is shaped by intense rivalry among digital‑therapeutics firms, pharmaceutical companies, and consumer‑tech players, each leveraging technology, strategic acquisitions, and partnerships to capture users seeking non‑pharmacologic solutions; recent M&A activity such as a major sleep‑device maker acquiring a CBT‑I app provider, and collaborations like a leading AI startup embedding generative models into personalized insomnia treatment platforms, are accelerating product differentiation and market penetration. 'Eisai Co., Ltd.', 'Idorsia Ltd.', 'Takeda Pharmaceutical Company Limited', 'Merck & Co., Inc.', 'Johnson & Johnson', 'Pfizer Inc.', 'Sanofi S.A.', 'Neurim Pharmaceuticals Ltd.', 'Vanda Pharmaceuticals Inc.', 'Axsome Therapeutics, Inc.', 'Harmony Biosciences Holdings, Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Viatris Inc.', 'Sun Pharmaceutical Industries Ltd.', 'Dr. Reddy's Laboratories Ltd.', 'Aurobindo Pharma Limited', 'Zydus Lifesciences Limited', 'Lupin Limited', 'Eli Lilly and Company', 'Neurocrine Biosciences, Inc.'
Growing public and clinical awareness of the importance of sleep health is prompting individuals to seek professional evaluation and management for insomnia, thereby expanding the patient base for therapeutic products and services. This heightened consciousness encourages preventive approaches, supports early diagnosis, and motivates adoption of evidence‑based interventions, which collectively stimulate demand across pharmaceutical, device, and behavioral segments of the market, fostering sustained growth. Healthcare providers are also integrating sleep assessments into routine check‑ups, which further normalizes treatment pathways and broadens market reach through multidisciplinary collaboration.
Digital Therapy Expansion: The proliferation of FDA‑cleared digital therapeutics and mobile sleep‑tracking platforms is reshaping how consumers address insomnia. Companies are integrating AI‑driven algorithms that personalize cognitive‑behavioral interventions, delivering therapy directly to smartphones. This shift reduces reliance on pharmacologic solutions, enhances patient engagement, and creates new revenue streams through subscription models. As clinicians endorse evidence‑based digital programs, insurers increasingly consider coverage, accelerating market adoption and prompting traditional manufacturers to form strategic partnerships with tech firms for distribution across retail and corporate wellness channels.
Why does North America Dominate the Global Insomnia Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
